{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:32:05Z","timestamp":1794576725154,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","award":["2018.0168"],"award-info":[{"award-number":["2018.0168"]}],"id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-02091"],"award-info":[{"award-number":["2021-02091"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Heteroresistance to vancomycin among methicillin-resistant\n                    <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    (MRSA) remains a diagnostic and therapeutic problem in clinical microbiology. In this prospective cohort study of 842 adult patients with MRSA bacteremia in S.\u00a0Korea, we investigate the prevalence, risk factors, and clinical implications of the heteroresistant vancomycin-intermediate\n                    <jats:italic>S. aureus<\/jats:italic>\n                    (hVISA) phenotype. The hVISA phenotype is detected in 22% of cases. Multivariable regression analysis reveals strong positive associations between hVISA and hospital-acquired infection, prior anti-MRSA therapy, vancomycin exposure, and particularly vancomycin MIC (odds ratio 15.2 per 1\u2009mg\/L increase, p\u2009&lt;\u20090.001). Strikingly, patients infected with hVISA strains have a lower 90-day mortality compared to those with fully susceptible strains (hazard ratio 0.66, p\u2009=\u20090.019), suggesting a possible trade-off between resistance and virulence. However, in hVISA strains treated with vancomycin, outcomes reverse: mortality more than doubled (HR 2.5, p\u2009&lt;\u20090.001), bacteremia persisted longer, and relapse rates increased fivefold. Using maximally selected rank statistics, we identify a PAP\u2013AUC threshold of 0.65 as the first clinically derived breakpoint predictive of mortality risk, providing an actionable definition of vancomycin heteroresistance. These findings underscore the clinical relevance of hVISA, and support routine testing for heteroresistance to inform treatment decisions.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-66118-8","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T14:47:48Z","timestamp":1765550868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Vancomycin heteroresistance (hVISA) in MRSA links to treatment failure and supports a revised PAP-AUC threshold"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5081-0138","authenticated-orcid":false,"given":"Nikos","family":"Fatsis-Kavalopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Kyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-3185","authenticated-orcid":false,"given":"Yong Pil","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongman","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Yun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6640-2174","authenticated-orcid":false,"given":"Dan I.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"66118_CR1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.5001\/omj.2019.37","volume":"34","author":"G Bahrain. Asokan","year":"2019","unstructured":"Allied Health Department, Public Health Program, College of Health Sciences, University of Bahrain, Manama, Bahrain. Asokan, G., Ramadhan, T., Ahmed, E. & Sanad, H. WHO Global priority pathogens list: a bibliometric analysis of Medline-PubMed for knowledge mobilization to infection prevention and control practices in Bahrain. OMJ 34, 184\u2013193 (2019).","journal-title":"OMJ"},{"key":"66118_CR2","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2147\/IDR.S177247","volume":"11","author":"M Haque","year":"2018","unstructured":"Haque, M., Sartelli, M., McKimm, J. & Bakar, M. A. Health care-associated infections \u2013 an overview. Infect. Drug Resistance 11, 2321\u20132333 (2018).","journal-title":"Infect. Drug Resistance"},{"key":"66118_CR3","doi-asserted-by":"crossref","unstructured":"Chatterjee, A., Rai, S., Guddattu, V., Mukhopadhyay, C. & Saravu, K. Is methicillin-resistant Staphylococcus aureus infection associated with higher mortality and morbidity in hospitalized patients? A cohort study of 551 patients from South Western India. Risk Manage. Healthcare Policy 11, 243\u2013250 (2018).","DOI":"10.2147\/RMHP.S176517"},{"key":"66118_CR4","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1001\/archinte.162.19.2229","volume":"162","author":"SI Blot","year":"2002","unstructured":"Blot, S. I., Vandewoude, K. H., Hoste, E. A. & Colardyn, F. A. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch. Intern. Med. 162, 2229\u20132235 (2002).","journal-title":"Arch. Intern. Med."},{"key":"66118_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1086\/502522","volume":"26","author":"SE Cosgrove","year":"2005","unstructured":"Cosgrove, S. E. et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hospital Epidemiol. 26, 166\u2013174 (2005).","journal-title":"Infect. Control Hospital Epidemiol."},{"key":"66118_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0195-6701(00)90807-7","volume":"46","author":"M MacKinnon","year":"2000","unstructured":"MacKinnon, M. & Allen, K. Long-term MRSA carriage in hospital patients. J. Hosp. Infect. 46, 216\u2013221 (2000).","journal-title":"J. Hosp. Infect."},{"key":"66118_CR7","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jinf.2010.09.021","volume":"61","author":"RR Kempker","year":"2010","unstructured":"Kempker, R. R., Farley, M. M., Ladson, J. L., Satola, S. & Ray, S. M. Association of methicillin-resistant Staphylococcus aureus (MRSA) USA300 genotype with mortality in MRSA bacteremia. J. Infect. 61, 372\u2013381 (2010).","journal-title":"J. Infect."},{"key":"66118_CR8","doi-asserted-by":"publisher","first-page":"106538","DOI":"10.1016\/j.ijantimicag.2022.106538","volume":"59","author":"VO Baede","year":"2022","unstructured":"Baede, V. O. et al. MRSA surveillance programmes worldwide: moving towards a harmonised international approach. Int. J. Antimicrobial agents 59, 106538 (2022).","journal-title":"Int. J. Antimicrobial agents"},{"key":"66118_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1128\/CMR.00058-14","volume":"28","author":"OM El-Halfawy","year":"2015","unstructured":"El-Halfawy, O. M. & Valvano, M. A. Antimicrobial heteroresistance: an emerging field in need of clarity. Clin. Microbiol. Rev. 28, 191\u2013207 (2015).","journal-title":"Clin. Microbiol. Rev."},{"key":"66118_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41579-019-0218-1","volume":"17","author":"DI Andersson","year":"2019","unstructured":"Andersson, D. I., Nicoloff, H. & Hjort, K. Mechanisms and clinical relevance of bacterial heteroresistance. Nat. Rev. Microbiol. 17, 479\u2013496 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"66118_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/jac\/47.4.399","volume":"47","author":"M Wootton","year":"2001","unstructured":"Wootton, M. et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrobial Chemother. 47, 399\u2013403 (2001).","journal-title":"J. Antimicrobial Chemother."},{"key":"66118_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/jac\/40.1.135","volume":"40","author":"K Hiramatsu","year":"1997","unstructured":"Hiramatsu, K. et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.  J. Antimicrobial Chemother. 40, 135\u2013136 (1997).","journal-title":"J. Antimicrobial Chemother."},{"key":"66118_CR13","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3390\/antibiotics10081014","volume":"10","author":"AE Maraolo","year":"2021","unstructured":"Maraolo, A. E., Giaccone, A., Gentile, I., Saracino, A. & Bavaro, D. F. Daptomycin versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bloodstream infection with or without endocarditis: a systematic review and meta-analysis. Antibiotics 10, 1014 (2021).","journal-title":"Antibiotics"},{"key":"66118_CR14","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1136\/hrt.2005.072595","volume":"92","author":"B Hoen","year":"2006","unstructured":"Hoen, B. Epidemiology and antibiotic treatment of infective endocarditis: an update. Heart 92, 1694 (2006).","journal-title":"Heart"},{"key":"66118_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jacc.2016.10.066","volume":"69","author":"TJ Cahill","year":"2017","unstructured":"Cahill, T. J. et al. Challenges in infective endocarditis. J. Am. Coll. Cardiol. 69, 325\u2013344 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"66118_CR16","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/QCO.0000000000000964","volume":"36","author":"G Tiseo","year":"2023","unstructured":"Tiseo, G., Galfo, V. & Falcone, M. What is the clinical significance of \u2018heteroresistance\u2019in nonfermenting Gram-negative strains? Curr. Opin. Infect. Dis. 36, 555\u2013563 (2023).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"66118_CR17","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1128\/AAC.00380-13","volume":"57","author":"AM Casapao","year":"2013","unstructured":"Casapao, A. M. et al. Clinical outcomes in patients with heterogeneous vancomycin-intermediate staphylococcus aureus bloodstream infection. Antimicrob. Agents Chemother. 57, 4252\u20134259 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"66118_CR18","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/jac\/dks131","volume":"67","author":"K-H Park","year":"2012","unstructured":"Park, K.-H. et al. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus. J. Antimicrobial Chemother. 67, 1843\u20131849 (2012).","journal-title":"J. Antimicrobial Chemother."},{"key":"66118_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3343\/alm.2016.36.3.235","volume":"36","author":"YR Koh","year":"2016","unstructured":"Koh, Y. R., Kim, K.-H., Chang, C. L. & Yi, J. Prevalence and clinical impact of heterogeneous vancomycin-intermediate Staphylococcus aureus isolated from hospitalized patients. Ann. Lab Med 36, 235\u2013243 (2016).","journal-title":"Ann. Lab Med"},{"key":"66118_CR20","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1128\/AAC.04765-14","volume":"59","author":"YP Chong","year":"2015","unstructured":"Chong, Y. P. et al. Clinical and microbiologic analysis of the risk factors for mortality in patients with heterogeneous vancomycin-intermediate staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 59, 3541\u20133547 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"66118_CR21","doi-asserted-by":"publisher","first-page":"e00333-24","DOI":"10.1128\/spectrum.00333-24","volume":"12","author":"JH Yun","year":"2024","unstructured":"Yun, J. H. et al. Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia. Microbiol Spectr. 12, e00333-24 (2024).","journal-title":"Microbiol Spectr."},{"key":"66118_CR22","doi-asserted-by":"publisher","first-page":"e21217","DOI":"10.1371\/journal.pone.0021217","volume":"6","author":"SJ Van Hal","year":"2011","unstructured":"Van Hal, S. J., Jones, M., Gosbell, I. B. & Paterson, D. L. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus bloodstream infections. PLoS ONE 6, e21217 (2011).","journal-title":"PLoS ONE"},{"key":"66118_CR23","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s10096-009-0741-5","volume":"28","author":"R Fong","year":"2009","unstructured":"Fong, R., Low, J., Koh, T. & Kurup, A. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur. J. Clin. Microbiol. Infect. Dis. 28, 983\u2013987 (2009).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"66118_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3109\/00365548.2012.723221","volume":"45","author":"T Takata","year":"2013","unstructured":"Takata, T. et al. Presence of both heterogeneous vancomycin-intermediate resistance and \u03b2-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection. Scand. J. Infect. Dis. 45, 203\u2013212 (2013).","journal-title":"Scand. J. Infect. Dis."},{"key":"66118_CR25","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1128\/AAC.02820-13","volume":"58","author":"AM Casapao","year":"2014","unstructured":"Casapao, A. M. et al. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrobial agents Chemother. 58, 4636\u20134641 (2014).","journal-title":"Antimicrobial agents Chemother."},{"key":"66118_CR26","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s12879-015-1215-2","volume":"15","author":"H-C Hu","year":"2015","unstructured":"Hu, H.-C. et al. Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units. BMC Infect. Dis. 15, 444 (2015).","journal-title":"BMC Infect. Dis."},{"key":"66118_CR27","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1128\/AAC.02388-15","volume":"60","author":"KC Claeys","year":"2016","unstructured":"Claeys, K. C. et al. Pneumonia caused by methicillin-resistant Staphylococcus aureus: does vancomycin heteroresistance matter? Antimicrob. Agents Chemother. 60, 1708\u20131716 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"66118_CR28","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1128\/AAC.01365-08","volume":"53","author":"KC Horne","year":"2009","unstructured":"Horne, K. C. et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrobial Agents Chemother. 53, 3447\u20133452 (2009).","journal-title":"Antimicrobial Agents Chemother."},{"key":"66118_CR29","doi-asserted-by":"publisher","first-page":"7868","DOI":"10.1038\/s41598-018-26277-9","volume":"8","author":"C-C Yang","year":"2018","unstructured":"Yang, C.-C. et al. Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility. Sci. Rep. 8, 7868 (2018).","journal-title":"Sci. Rep."},{"key":"66118_CR30","doi-asserted-by":"publisher","unstructured":"Heyman, G. et al. Prevalence, misclassification, and clinical consequences of the heteroresistant phenotype in Escherichia coli bloodstream infections in patients in Uppsala, Sweden: a retrospective cohort study. Lancet Microbe https:\/\/doi.org\/10.1016\/j.lanmic.2024.101010.","DOI":"10.1016\/j.lanmic.2024.101010"},{"key":"66118_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.meegid.2013.03.047","volume":"21","author":"BP Howden","year":"2014","unstructured":"Howden, B. P., Peleg, A. Y. & Stinear, T. P. The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. Infect. Genet. Evol. 21, 575\u2013582 (2014).","journal-title":"Infect. Genet. Evol."},{"key":"66118_CR32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1128\/AAC.50.2.428-438.2006","volume":"50","author":"L Cui","year":"2006","unstructured":"Cui, L. et al. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50, 428\u2013438 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"66118_CR33","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1128\/AAC.00422-06","volume":"50","author":"BP Howden","year":"2006","unstructured":"Howden, B. P., Johnson, P. D. R., Ward, P. B., Stinear, T. P. & Davies, J. K. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 50, 3039\u20133047 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"66118_CR34","doi-asserted-by":"publisher","first-page":"7103","DOI":"10.1128\/JB.185.24.7103-7110.2003","volume":"185","author":"K Sieradzki","year":"2003","unstructured":"Sieradzki, K. & Tomasz, A. Alterations of Cell Wall structure and MetabolismAccompany reduced susceptibility to vancomycin in an IsogenicSeries of clinical isolates of Staphylococcusaureus. J. Bacteriol. 185, 7103\u20137110 (2003).","journal-title":"J. Bacteriol."},{"key":"66118_CR35","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1128\/AAC.47.10.3040-3045.2003","volume":"47","author":"C Liu","year":"2003","unstructured":"Liu, C. & Chambers, H. F. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47, 3040\u20133045 (2003).","journal-title":"Antimicrob. Agents Chemother."},{"key":"66118_CR36","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nrmicro2319","volume":"8","author":"DI Andersson","year":"2010","unstructured":"Andersson, D. I. & Hughes, D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev. Microbiol. 8, 260\u2013271 (2010).","journal-title":"Nat. Rev. Microbiol."},{"key":"66118_CR37","doi-asserted-by":"publisher","first-page":"e3002457","DOI":"10.1371\/journal.pbio.3002457","volume":"22","author":"S Heidarian","year":"2024","unstructured":"Heidarian, S., Guliaev, A., Nicoloff, H., Hjort, K. & Andersson, D. I. High prevalence of heteroresistance in Staphylococcus aureus is caused by a multitude of mutations in core genes. PLoS Biol. 22, e3002457 (2024).","journal-title":"PLoS Biol."},{"key":"66118_CR38","doi-asserted-by":"publisher","first-page":"eadv4558","DOI":"10.1126\/sciadv.adv4558","volume":"11","author":"SN Agnihotri","year":"2025","unstructured":"Agnihotri, S. N., Fatsis-Kavalopoulos, N., Windhager, J., Tenje, M. & Andersson, D. I. Droplet microfluidics\u2013based detection of rare antibiotic-resistant subpopulations in Escherichia coli from bloodstream infections. Sci. Adv. 11, eadv4558 (2025).","journal-title":"Sci. Adv."},{"key":"66118_CR39","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1473-3099(20)30447-3","volume":"20","author":"R Kuehl","year":"2020","unstructured":"Kuehl, R. et al. Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study.  Lancet Infect. Dis. 20, 1409\u20131417 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"66118_CR40","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1345\/aph.1M526","volume":"44","author":"SL Rong","year":"2010","unstructured":"Rong, S. L. & Leonard, S. N. Heterogeneous vancomycin resistance in staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance. Ann. Pharmacother. 44, 844\u2013850 (2010).","journal-title":"Ann. Pharmacother."},{"key":"66118_CR41","doi-asserted-by":"publisher","first-page":"e3001346","DOI":"10.1371\/journal.pbio.3001346","volume":"19","author":"VI Band","year":"2021","unstructured":"Band, V. I. & Weiss, D. S. Heteroresistance to beta-lactam antibiotics may often be a stage in the progression to antibiotic resistance. PLOS Biol. 19, e3001346 (2021).","journal-title":"PLOS Biol."},{"key":"66118_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1017\/S0950268800051682","volume":"113","author":"N Kobayashi","year":"1994","unstructured":"Kobayashi, N. et al. Detection of mecA, femA, and femB genes in clinical strains of staphylococci using polymerase chain reaction. Epidemiol. Infect. 113, 259\u2013266 (1994).","journal-title":"Epidemiol. Infect."},{"key":"66118_CR43","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1093\/cid\/ciac364","volume":"75","author":"TL Holland","year":"2022","unstructured":"Holland, T. L., Bayer, A. S. & Fowler, V. G. Jr Persistent methicillin-Resistant Staphylococcus aureus bacteremia: resetting the clock for optimal management. Clin. Infect. Dis. 75, 1668\u20131674 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"66118_CR44","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","volume":"101","author":"RC Bone","year":"1992","unstructured":"Bone, R. C. et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101, 1644\u20131655 (1992).","journal-title":"Chest"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66118-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66118-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66118-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T13:01:36Z","timestamp":1766149296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66118-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["66118"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66118-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11251"}}